SELLAS Life Sciences Group, Inc. cotiza a 11.93 USD y tiene una capitalización bursátil de $2.3B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and …
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | — | $-0.05 | $-0.06 |
| Estimado | $-0.05 | $-0.04 | $-0.06 | $-0.08 |
| Sorpresa | — | — | +16.7% | +25.0% |
| Métrica | SLS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -37.9% | -40.4% | +2.5% |
| ROA | -34.3% | -32.0% | -2.3% |
| Current Ratio | 10.72 | 2.84 | +7.88 |
| Debt / Equity | — | 0.28 | — |